Tildrakizumab (TIL), anti–IL-23p19 monoclonal ab, superior to PBO in phase 2b trial results in PsA. https://t.co/i0vIEHD4hx #ACR19 @RheumNow abs#2878 https://t.co/OmlhZfGdJi
Links:
Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2b Study to …
http://ow.ly/TrPq50x3C2t
Nov-13-2019
